David Stock - Concepedia

Author

David Stock

Also Known As

D STOCK, D Stock, D. A. STOCK, D. Stock, D.A. Stock, David A Stock, David A. Stock, David Stock, Pedro Cahn, Stock, D. (Brookhaven National Lab., Upton, NY (United States))

Publications

3.1K

Citations

H-Index

Concepts

All Affiliations

Bristol-Myers Squibb (United States)Biohaven Pharmaceuticals (United States)Albert Einstein College of Medicine King's College London Wellcome Trust

About

David Stock is an author at Bristol-Myers Squibb (United States) specializing in medicine, pharmacology, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	15	17	1.7K
2	Health Sciences	4	4	174
3	Applied Physiology	2	2	138
4	Engineering	1	1	97
5	Natural Sciences	1	1	14

David Stock

Publications

Citations

H-Index

Page 1

	Year	Citations
Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial Robert Croop, Peter J. Goadsby, David Stock, The Lancet Acute TreatmentCluster HeadacheMedicinePlacebo-controlled TrialPharmacotherapy	2019	379
Rimegepant, an Oral Calcitonin Gene–Related Peptide Receptor Antagonist, for Migraine Richard B. Lipton, Robert Croop, Elyse Stock, New England Journal of Medicine	2019	379
Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial Robert Croop, Richard B. Lipton, David Kudrow, The Lancet Cluster HeadacheOral RimegepantPlacebo-controlled TrialPharmacotherapyNeurology	2020	334
BMS-927711 for the acute treatment of migraine: A double-blind, randomized, placebo controlled, dose-ranging trial Ronald N. Marcus, Peter J. Goadsby, David W. Dodick, Cephalalgia	2013	285
4-Thiazolidinones: novel inhibitors of the bacterial enzyme murB Charles J. Andres, Joanne J. Bronson, Stanley V. D’Andrea, Bioorganic & Medicinal Chemistry Letters MedicineBacterial Enzyme MurbAntibacterial AgentAntimicrobial ChemotherapyMicrobiology	2000	218
BMS-232632, a Highly Potent Human Immunodeficiency Virus Protease Inhibitor That Can Be Used in Combination with Other Available Antiretroviral Agents Brett S. Robinson, Keith Riccardi, Yi-Fei Gong, Antimicrobial Agents and Chemotherapy	2000	195
<i>In Vitro</i>Antiviral Characteristics of HIV-1 Attachment Inhibitor BMS-626529, the Active Component of the Prodrug BMS-663068 Beata Nowicka-Sans, Yi-Fei Gong, Brian McAuliffe, Antimicrobial Agents and Chemotherapy Prodrug Bms-663068Hiv-1 Gp120MedicineImmunologyAntiviral Response	2012	137
Safety, tolerability, and efficacy of zavegepant 10 mg nasal spray for the acute treatment of migraine in the USA: a phase 3, double-blind, randomised, placebo-controlled multicentre trial Richard B. Lipton, Robert Croop, David Stock, The Lancet Neurology Cluster HeadachePharmacotherapyNeurologyMg Nasal SprayMedicine	2023	136
In Vitro Resistance Profile of the Human Immunodeficiency Virus Type 1 Protease Inhibitor BMS-232632 Yi-Fei Gong, Brett S. Robinson, Ronald E. Rose, Antimicrobial Agents and Chemotherapy	2000	132
An Empirical Process for the Design of High-Throughput Screening Deck Filters Bradley C. Pearce, Michael J. Sofia, Andrew C. Good, Journal of Chemical Information and Modeling Objective IdentificationEngineeringHit IdentificationForensic ChemistryDrug Screening	2006	97

Page 1